Pharma SNP consortium(PSC)

摘要

The 43 member companies of the Japan Pharmaceutical Manufactures Associatioin (JPMA)established the Pharma SNP Consortium (PSC),a non-profit organization,which will implement research programs over the three years between 2000-2003 with a total budget of 1 billion yen.The objective of the PSC are to determine where SNPs influencing pharmacokinetics exist and how ofter they occur in Japanese population.The expression and functional analyses of variants generated under the influence of SNP will also bestudied.The following are concrete research themes of the PSC:Standardiation to collect samples from human donors;informed consent,protection of privacy(anonymity,informationmanagement system,etc.),ethice committee,and procedures(blood sampling,storage,etc.).And the analysis on gene polymorphisms (SNPs)related with pharmacokinetics;to identify SNPs of approximately 180 pharmacokinetics ralated genes,which are drug metabolizing enzymes and transporters,to analyze the allelic frequency of SNPs on a general Japanese population group composed a about 800 individuals,to generate a database for the analysis of SNPs allelic frequency,and to express variants in insect cells,analyze their function and examine the influence on the drug responses.It is hoped that the PCS's plan will contribute to the development of the healthcare by constructing a common basis for the durg response analysis,create a nore effective environment for the research on the human genome by the private sector in Japan by making standards to obtain blood samples,and furthermore facilitate discovery and development of safer and more effective medicines by cooperting with the Millennium Project.